CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Jan. 02, 2021	Dec. 28, 2019	Dec. 29, 2018
Operating activities:
Net income	$ 75,041	$ 119,447	$ 223,568
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation and amortization	50,677	45,017	44,061
Amortization of deferred financing costs and debt discount	8,845	9,318	8,539
Goodwill impairment	3,665	0	0
Impairment of intangible and long-lived assets	1,372	307	27
Share-based compensation expense	55,013	20,471	20,188
Deferred tax benefit	(1,440)	(9,424)	(13,673)
Allowance for doubtful accounts	411	(123)	130
Reserve for inventory obsolescence	16,425	8,710	7,906
Foreign currency exchange rate loss	719	1,235	2,036
Changes in cash due to:
Receivables	(3,600)	1,331	(7,999)
Inventories	(25,940)	(9,127)	(1,148)
Prepaid expenses	(5,081)	13,619	(3,991)
Accounts payable	(4,045)	1,347	2,224
Accrued liabilities	(29,421)	(6,968)	16,600
Deferred revenue	(11,583)	6,199	(17,198)
Other long term assets and liabilities, net	1,859	(878)	(13,001)
Income taxes	3,023	(18,098)	27,323
Cash provided by operating activities	135,940	182,383	295,592
Investing activities:
Capital expenditures	(21,490)	(17,159)	(19,050)
Capitalized software expenditures	(28,941)	(30,824)	(27,763)
Cash paid for acquisitions	(10,037)	(4,060)	(7,100)
Other items, net	(5,123)	(580)	(10,045)
Cash used for investing activities	(65,591)	(52,623)	(63,958)
Financing activities:
Net (payments) borrowings on revolver	0	0	(25,000)
Payments on long-term debt	(96,250)	(177,000)	(57,750)
Taxes paid related to net share settlement of equity awards	(6,798)	(6,582)	(25,020)
Proceeds from stock options exercised	8,176	1,076	33,417
Other items, net	(667)	(487)	0
Cash used for financing activities	(95,539)	(182,993)	(74,353)
Effect of exchange rate changes on cash and cash equivalents	8,341	(1,005)	(3,361)
Net (decrease) increase in cash and cash equivalents	(16,849)	(54,238)	153,920
Cash and cash equivalents, beginning of period	182,736	236,974	83,054
Cash and cash equivalents, end of period	$ 165,887	$ 182,736	$ 236,974